Evaluating Clinical Outcomes of Recombinant Human Bone Morphogenetic Protein-2 with ECM and BMAC for Ankle Osteochondral Lesions with Subchondral Damage
In brief
A retrospective case series reviewed patients whose ankle osteochondral lesions with damage to the underlying bone were repaired using recombinant bone morphogenetic protein, extracellular matrix and bone marrow aspirate concentrate (BMAC). The authors report improved function and pain scores at over a year and a low complication rate, but there was no comparison group.
Read the original paper (opens in a new tab)
Citation, as listed in the BMAC guidelines
27. Evaluating Clinical Outcomes of Recombinant Human Bone Morphogenetic Protein-2 with ECM and BMAC for Ankle Osteochondral Lesions with Subchondral Damage. Foot & Ankle International (SAGE). 2025. https://journals.sagepub.com/doi/10.1177/24730114251398507
A summary of published research for general information. It does not replace a consultation; whether a treatment suits you is decided by a specialist after examination.
More from the BMAC guidelines
- Exploring Bias Patterns in Systematic Reviews and Meta-Analyses of Bone Marrow Aspirate Concentrate2026
- Intra-articular Injections for Shoulder Arthritis in Adults: A Systematic Review2025
- Centrifuge-Free Bone Marrow Aspirate Harvest for Orthopaedic Applications2025
- Concentrated Bone Marrow Aspirate with Extracellular Matrix Grafting for Osteochondral Lesions of the Talus in Pediatric and Adolescent Patients2025

